The Role of Delaware Form 700 in Monetizing the Research and Development Tax Credit

Delaware Form 700, formally titled the Delaware Income Tax Credit Schedule, is the mandatory final document used to formally apply approved state tax incentives, such as the Research and Development (R&D) Tax Credit, against a taxpayer’s annual Delaware income tax liability. This schedule serves as the essential bridge between the Delaware Division of Revenue’s (DOR) prior approval of the credit amount and the taxpayer’s final calculation of tax due or refundable balance, requiring the attachment of the prior approval forms.

The Compliance Funnel: Form 700 in Context

Form 700 is not the application instrument for the R&D credit; rather, it functions solely as the schedule for claiming the value of a credit that has been pre-approved by the DOR.1 The initial application, calculation, and approval must be completed and received by the DOR using the applicable Delaware Form 2070AC or 2071AC, depending on the tax year. Once the Division of Revenue approves the credit amount, that precise figure is transferred to the relevant lines on Form 700.1

This procedural sequence underscores a key administrative requirement: the claim asserted on Form 700 is dependent upon supporting documentation establishing the credit’s validity. The DOR mandates that the approved R&D credit amount from Form 2070AC/2071AC must be attached, along with Form 700 itself, to the taxpayer’s primary Delaware annual income tax return (such as the corporate income tax return).1 This specific instruction requiring the attachment of the pre-approval documents confirms that the burden of proving the credit’s validity rests with the taxpayer at the point of filing the return. This procedural safeguard ensures that the approval document is physically paired with the claim, distinguishing Delaware’s process from self-assessed credits found in other tax jurisdictions.

The Legal Foundation: 30 Del. Code § 2070 and the R&D Credit

The Credit for Research and Development Expenses in Delaware is a statutory incentive authorized under 30 Del. Code § 2070, and the program is administered by the Delaware Division of Revenue.3 This credit is available to both corporations and flow-through entities engaged in qualified research activities within the state.1

Federal Nexus and Eligibility Requirements

A crucial feature of the Delaware R&D credit is its alignment with federal standards. To qualify for the state credit, the underlying R&D activity must meet the definitions established under Internal Revenue Code (IRC) Section 41. Any R&D activity conducted within Delaware that qualifies for the federal R&D tax credit automatically qualifies for the corresponding state credit.6 Consequently, taxpayers are required to attach a copy of the federal research credit Form 6765, Credit for Increasing Research Activities, to their Delaware application package (Form 2070AC/2071AC).1 This linkage ensures definitional consistency and procedural integrity between the federal and state claims.

The Strategic Impact of Post-2016 Legislative Enhancements

The Delaware R&D credit program underwent dramatic strategic enhancements with the signing of the “Commitment to Innovation Act” in March 2016, with provisions effective for tax periods beginning after December 31, 2016.8 These changes significantly improved the credit’s utility and attractiveness for innovative businesses.

Full Refundability

The most impactful change was making the credit fully refundable.2 If the approved credit amount transferred to Form 700 exceeds the taxpayer’s Delaware income tax liability, the unused portion is paid directly to the taxpayer as a tax refund.8 This contrasts sharply with the pre-2017 system, where the credit was non-refundable and limited to 50% of the tax liability otherwise due, with any unused portion requiring carryforward for up to 15 years.1

The shift to full refundability transforms the credit into a critical cash flow mechanism, especially for R&D-heavy companies, such as startups or pre-revenue biotech firms, that may not yet be generating profits.3 The ability to monetize the credit immediately, rather than waiting to offset future tax liabilities, provides immediate, non-dilutive capital, which establishes a strategic advantage compared to nearby states.11

Elimination of the Annual Cap

The legislation also removed the prior $5 million aggregate annual limit on credits awarded statewide.2 Historically, if the total amount of credits approved by the DOR exceeded this $5 million cap, credits would be prorated proportionally among all eligible applicants.6 The elimination of the cap means all approved companies now receive the full calculated credit amount, removing the financial risk associated with program oversubscription and ensuring predictability in expected cash benefits.8

Credit Calculation Methods and the Small Business Incentive

Delaware provides taxpayers with two distinct methods for calculating the R&D credit amount, and a taxpayer must make an annual election regarding which methodology to use.5 This election is independent of the taxpayer’s choice of method for calculating the federal R&D credit, allowing for maximum flexibility in tax planning.3

Calculation Options

The two methods available for calculating the credit are set forth in 30 Del. Code § 2070(a).4

Method 1: Excess Qualified Research Expenses (QREs)

This method calculates the credit based on the amount of qualified research expenses exceeding a pre-established base amount.

1. General Rate: For taxpayers with average annual gross receipts exceeding $\$20$ million, the credit equals $10\%$ of the excess of total Delaware QREs over the Delaware base amount.4
2. Small Business Rate: For small businesses, the rate is enhanced to $20\%$ of the excess QREs over the base amount.5

Method 2: Apportioned Federal Alternative Simplified Credit (ASC)

This method ties the state credit directly to the federal ASC calculation under IRC $\S 41(c)(5)$.

1. General Rate: For larger businesses, the credit is $50\%$ of Delaware’s apportioned share of the federal ASC.5
2. Small Business Rate: For small businesses, the percentage is enhanced to $100\%$ of Delaware’s apportioned share of the federal ASC.5

Delaware’s apportioned share of the federal credit is calculated by multiplying the federal ASC amount by a percentage equal to the ratio of the taxpayer’s Delaware QREs for the taxable year to the taxpayer’s total qualified research and development expenses for the taxable year.5

Defining the “Small Business” Advantage

The enhanced rates (20% under Method 1, 100% under Method 2) are reserved for “small businesses,” defined specifically as any taxpayer with average annual gross receipts, determined by IRC $\S 41(c)(1)(B)$, not in excess of $\$20,000,000$.5 This lower threshold provides substantial leverage for smaller companies that are heavily invested in innovation.5

The enhanced rates demonstrate a specific state policy to support growth-stage companies. The decision to enhance the ASC election (Method 2) to $100\%$ for small businesses is particularly strategic, allowing those businesses to claim the full benefit of their federally calculated credit that is attributable to Delaware research, often yielding the largest immediate cash benefit due to the credit’s refundability.

Table 1: Statutory R&D Credit Calculation Rates (30 Del. Code § 2070)

Division of Revenue Guidance: Pre-Form 700 Compliance

The compliance pathway for the R&D credit is strictly regulated by the DOR and requires that the application phase be completed well in advance of the final income tax return filing, which uses Form 700.

The Application Phase: Forms 2070AC/2071AC

The taxpayer must first submit the R&D Credit application, utilizing Delaware Form 2070AC or 2071AC (depending on the tax year). The filing deadline for this application is mandatory: it must be filed by September 15th after the end of the taxable year in which the R&D expenses were incurred.1

This September 15th deadline carries significant importance because it typically precedes the extended due date for the taxpayer’s primary corporate income tax return (which is often October 15th). This means the taxpayer must expedite the R&D calculation and submit it for DOR approval before the final return, where Form 700 resides, is finalized and filed.7 The inability to meet this specific application deadline effectively nullifies the current year credit, regardless of the timely filing of the corporate tax return. This structure mandates a proactive approach to R&D credit compliance.

The application submission must include the completed Form 2070AC/2071AC, a copy of the federal Form 6765, a detailed breakdown of QREs incurred within Delaware, and supporting calculation schedules.1

The Approval and Claiming Mechanism

Once the DOR reviews the application and confirms the eligibility and calculation, the taxpayer receives an approval letter or the approved form back from the Division of Revenue.13 This approved credit amount is the specific figure that must be transferred and entered onto the appropriate lines within the Research & Development Credits section of Delaware Form 700, Part B.1

The filing requirements dictate that both the DOR approval letter and the approved Form 2070AC/2071AC must be attached to the taxpayer’s annual Delaware return, alongside the completed Form 700.2

Form 700 Mechanics: Transferring and Allocating the Credit

Form 700 serves as the singular mechanism through which the pre-approved R&D credit is integrated into the overall calculation of the taxpayer’s income tax liability. Part B of Form 700 is dedicated to the Credit Computation, with specific lines reserved for Research & Development Credits.14

Handling Prior-Year Credits (Line 9)

Line 9 of the R&D Credits section is designated for entering the “Credit carryover from previous year”.14 While the post-2017 refundability provision significantly reduces the likelihood that a taxpayer will need to carry over a current-year credit (since unused credits are now generally refunded), this line remains active for historical purposes, such as utilizing any remaining carryovers generated during the pre-2017 non-refundable era, or specific credits that had been subject to the historical 50% tax liability limitation.9

Entering Current-Year Approved Credits (Lines 10 and 11)

The key function of Form 700 is to correctly allocate the current year’s approved credit across different entity types, which is done on Line 10.14

• C Corporations (Line 10(a)): A C corporation enters the total approved current year credit from the DOR approval documentation.14
• Flow-Through Entities: For S corporations, partnerships, and sole proprietors, specific allocation rules apply to ensure the credit flows correctly to the ultimate taxpayer.12

• S Corporation (Line 10(b)): The total approved entity-level credit must be multiplied by the percentage of stockholder ownership, and the resulting amount is entered here.12
• Partnership (Line 10(c)): Similarly, the approved credit must be multiplied by the percentage ownership of each partner.12
• Sole Proprietor (Line 10(d)): The total approved credit amount is entered directly, as the individual is the sole claimant.12

Line 11 aggregates the amounts from lines 10(a) through 10(d) to determine the total current year R&D credits being claimed.14

Table 2: Delaware Form 700: R&D Credit Allocation (Part B, Research & Development Credits Section)

The Refund Determination

Once the total R&D credits (Line 9 plus Line 11) are determined on Form 700, they are applied against the total income tax liability calculated on the primary Delaware tax form. Because the credit is fully refundable for tax years beginning after 2016, if the total approved credit amount listed on Form 700 exceeds the taxpayer’s gross liability, the resulting negative tax figure is processed by the DOR as a cash refund.2 This defines the function of Form 700 not merely as a liability reduction schedule, but as the final instrument for initiating a state capital distribution related to qualified R&D activities.

Comprehensive Example: Small Business R&D Credit and Form 700 Utilization

To illustrate the critical linkage between the calculation, approval, and application on Form 700, consider the following scenario involving a small, innovative C-corporation.

Scenario Setup: Innovate DE Corp (C-Corp)

Innovate DE Corp, a Delaware C-Corporation engaged in advanced manufacturing, qualifies as a small business.

• Taxpayer Status: C-Corporation, Small Business (Average annual gross receipts: $\$15,000,000$).
• R&D Financial Data (2024 Tax Year): Delaware Qualified Research Expenses (QREs): $\$400,000$. Total QREs (Federal): $\$500,000$.
• Federal Context: The corporation calculates a Federal Alternative Simplified Credit (ASC) of $\$50,000$ on Federal Form 6765.
• Delaware Tax Liability: Current year Delaware income tax liability (before credits): $\$10,000$.

Step 1 & 2: Calculation and Application (Form 2070AC/2071AC)

1. Strategic Election: Given its small business status and a favorable federal ASC calculation, Innovate DE Corp elects Calculation Method 2: $100\%$ of Delaware’s apportioned share of the ASC.5
2. Apportionment: The apportionment ratio is calculated by dividing Delaware QREs by Total QREs: $\frac{\$400,000}{\$500,000} = 80\%$.
3. Delaware Approved Credit: The credit is $100\%$ multiplied by the apportioned federal ASC amount: $100\% \times (\$50,000 \text{ Federal ASC} \times 80\% \text{ Apportionment}) = \$40,000$.
4. Compliance: Innovate DE Corp files Form 2070AC/2071AC with the DOR by September 15, 2025 (for the 2024 tax year), attaching Form 6765.1 The DOR subsequently approves the $\$40,000$ credit.

Step 3: Income Tax Liability Offset and Refund Determination

1. Gross Liability: $\$10,000$.
2. Approved Credit Applied: $\$40,000$.
3. Net Result: The liability is offset: $\$10,000$ (Liability) – $\$40,000$ (Credit) $= -\$30,000$.
4. Outcome: Because the credit is fully refundable, the negative balance of $\$30,000$ is paid to Innovate DE Corp as a direct cash refund.6

Step 4: Completing Delaware Form 700

The $\$40,000$ approved credit is formally claimed by transferring this amount to the Research & Development Credit section of Form 700. Since Innovate DE Corp is a C-Corporation, the amount is placed on Line 10(a).

Table 3: Example Data Entry on Delaware Form 700 (Part B)

Conclusion and Strategic Insights

The Delaware R&D tax credit, administered through a formal pre-approval and application process culminating in Delaware Form 700, provides a compelling incentive structure designed to support innovation within the state. Delaware’s policy updates—the elimination of the annual cap and the introduction of full refundability—have been critical factors in strengthening the state’s position as a hub for R&D-intensive industries, evidenced by the state ranking 6th in the U.S. for industrial R&D intensity.11

Form 700 represents the final, essential compliance step that formalizes the monetization of the approved credit. Compliance professionals must recognize that the claim asserted on Form 700 hinges entirely on the strict adherence to the DOR’s pre-approval process (Forms 2070AC/2071AC), which must be filed by the September 15th deadline.1 A failure to secure DOR approval by that deadline renders the use of Form 700 for the current-year credit impossible.

For tax planning purposes, businesses are required to annually evaluate the two calculation methodologies (Excess QREs vs. Apportioned ASC) based on their current year’s QREs and federal tax posture to maximize the approved credit amount before transferring it to Form 700.5 The enhanced rates for small businesses, particularly the $100\%$ Apportioned ASC method, are a key policy tool that maximizes the potential refundable cash benefit for early-stage companies.

Finally, proper completion of Form 700 necessitates rigorous audit preparedness. The requirement for flow-through entities (S corporations and partnerships) to allocate the entity-level credit on Lines 10(b) and 10(c) requires meticulous record-keeping to ensure the prorated credits are accurately reported to individual owners.12 Tax departments must maintain robust documentation—including the federal Form 6765, the QRE calculations, the DOR approval form, and Form 700—to substantiate the claim and support the final tax return filing.1

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/